Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Inherited Immune Deficiencies
Bottom Line
View on ClinicalTrials.gov: NCT00426517 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Campath 1H (Drug); Busulfan (Drug); Horse Anti-human Thymocyte Globulin (h-ATG) (Drug); Total Body Irradiation (TBI) (Drug); Sirolimus or equivalent based on response (Drug)
- Age
- Pediatric, Adult · 2+ yrs
- Sex
- All
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Primary completion
- Nov 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Stem Cell Transplant Engraftment |
7; 31; 3; 0 | — |
| SECONDARY Engraftment Without Development of GVHD |
6; 30; 3; NA | — |
| SECONDARY Participants With Established Stable Mixed Chimerism |
7; 30; 3; NA | — |
| SECONDARY Days to CD3 Count Greater Than 100 u/L |
355; 284; 16; NA | — |
| SECONDARY Days to Absolute Neutrophil Recovery (ANC) |
19.42; 77.44; 25.5; NA | — |
| SECONDARY Number of RBC Transfusions Per Subject |
1.71; 7.08; 4; NA | — |
| SECONDARY Days to Platelet Recovery |
31; 31.9; 32.6; NA | — |
| SECONDARY Incidence of Cytomegalovirus (CMV) Disease |
0; 0; 0; 0 | — |
Summary
Eligibility Criteria
- INCLUSION CRITERIA:
PATIENTS (RECIPIENT)
- Must have confirmed genetic diagnosis of XSCID (common gamma chain disorder) by identification of a mutation in the IL2RG gene or by demonstrating failure to detect gamma c protein in patient immune blood cells.
- Must have sufficient complications from underlying disease to warrant undergoing transplantation as defined as follows:.
Clinical Criteria: (greater than or equal to 1 must be present)
i. Infections (not including molluscum, warts or mucocutaneous candidiasis; see vii and viii below): 3 significant new or chronic active infections during the 2 years preceding evaluation for enrollment, with each infection accounting for one criteria.
Infections are defined as an objective sign of infection (fever >38.30C [1010F] or neutrophilia or pain/redness/swelling or radiologic/ultrasound imaging evidence or typical lesion or histology or new severe diarrhea or cough with sputum production). In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician's intent to treat a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)
- Treatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics . 14 days OR
- Hospitalization of any duration for infection OR
- Isolation of a bacteria, fungus, or virus from biopsy, skin lesion, blood, nasal washing, bronchoscopy, cerebrospinal fluid or stool likely to be an etiologic agent of infection
ii. Chronic pulmonary disease as defined by:
- Bronchiectasis by x-ray computerized tomography OR
- Pulmonary function test (PFT) evidence for restrictive or obstructive disease that is . 60% of Predicted for Age OR
- Pulse oximetry . 94% in room air (if patient is too young to comply with performance of PFTs).
iii. Gastrointestinal enteropathy:
- Diarrhea-watery stools . 3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion # i. above) OR
- Endoscopic evidence (gross and histologic) for enteropathy (endoscopy will only be performed if medically indicated) OR
- Other evidence of enteropathy or bacterial overgrowth syndrome: including malabsorption of fat soluble vitamin(s), abnormal D-xylose absorption, abnormal hydrogen breath test, evidence of protein losing enteropathy (for example increasingly high or frequent dosing of intravenous gamma globulin supplement required to maintain blood IgG level).
iv. Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition.
v. Auto- or allo-immunity: Examples must include objective physical findings that include, but are not limited to any one of alopecia, severe rashes, uveitis, joint pain with redness or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality.
vi. Failure to grow in height: . 3rd percentile for age
vii. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of 10 lesions or there are two or more lesions at each of two or more widely separated anatomic sites; or there are 3 warts at different anatomic sites at the same time; or the patient has both
molluscum and warts)
viii. Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion)
ix. Hypogammaglobulinemia: requires regular IgG supplementation
Ages 2 years 40 years.
HLA-matched family donor available or an HLA matched unrelated PBSC graft (10/10 or 9/10 mismatch) available, or a minimum of 4/6 HLA matched cord blood product. (If the size of the cord blood graft is les
Data sourced from ClinicalTrials.gov (NCT00426517). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.